The U.S. Food and Drug Administration (FDA) has issued draft guidance outlining a framework that could help speed the development and approval of personalized treatments for ultra-rare diseases, such as Aromatic l-amino acid decarboxylase (AADC) deficiency. The framework, “Considerations for the Use of the Plausible Mechanism Framework to…